OncoMed-Celgene Wins In Vivo Alliance of the Year

In Vivo

December 19, 2013

In Vivo awarded the OncoMed-Celgene collaboration deal the “Alliance of the Year” award, which acknowledged “it was one of the most complicated agreements of the year in biopharmaceuticals.” 

Latham & Watkins Life Science Transactions global Chair Judith Hasko commented, “We are proud of our work for OncoMed in its alliance with Celgene, which is among the largest early clinical deals in biotech history.” The anti-cancer stem cell  therapeutic deal is valued up to US$3.3 billion.

Notice: We appreciate your interest in Latham & Watkins. If your inquiry relates to a legal matter and you are not already a current client of the firm, please do not transmit any confidential information to us. Before taking on a representation, we must determine whether we are in a position to assist you and agree on the terms and conditions of engagement with you. Until we have completed such steps, we will not be deemed to have a lawyer-client relationship with you, and will have no duty to keep confidential the information we receive from you. Thank you for your understanding.